PT  - JOURNAL ARTICLE
AU  - Shaghayegh Mohsenian Naghani
AU  - Mark MPM Jansen
AU  - Tessa Jaspers
AU  - Diane Bastiaans
AU  - David Burger
TI  - Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
AID  - 10.1136/ejhpharm-2020-002596
DP  - 2021 May 13
TA  - European Journal of Hospital Pharmacy
PG  - ejhpharm-2020-002596
4099  - http://ejhp.bmj.com/content/early/2021/05/13/ejhpharm-2020-002596.short
4100  - http://ejhp.bmj.com/content/early/2021/05/13/ejhpharm-2020-002596.full
AB  - Objective Lopinavir/ritonavir (LPV/RTV) exposure is decreased in children after crushing the tablets. Whether exposure is also decreased in adult patients is not known. This study evaluated the exposure of LPV/RTV in adult patients after administration of crushed LPV/RTV tablets.Methods Blood samples were drawn from patients with COVID-19 who were receiving crushed LPV/RTV 400/100 mg tablets twice daily.Results Plasma concentrations for 11 patients with COVID-19 (eight men, mean age 62.6 years) were included. The measured plasma concentrations of LPV were substantially higher than reported for patients with HIV.Conclusions There is adequate exposure from crushed LPV/RTV tablets, but because of limited experience, therapeutic drug monitoring is still advised.All data relevant to the study are included in the article or uploaded as supplementary information.